Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVM CEL-SCI	$10.43 +12.0%	$6.12	$1.98 ▼ $39.30	$71.78M	0.52	373,965 shs	514,794 shs
IKT Inhibikase Therapeutics	$1.80 -2.2%	$1.77	$1.12 ▼ $4.20	$134.13M	0.9	188,350 shs	71,026 shs
PLX Protalix BioTherapeutics	$1.55	$1.51	$0.90 ▼ $3.10	$123.59M	-0.21	830,486 shs	672,081 shs
PRTO Proteon Therapeutics	$3.14 -2.8%	$19.37	$0.22 ▼ $3.94	$69.64M	0.6	1.11 million shs	101,859 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVM CEL-SCI	-28.60%	+1.53%	+30.21%	+343.33%	-71.40%
IKT Inhibikase Therapeutics	+2.79%	+9.52%	+8.24%	-9.36%	+32.37%
PLX Protalix BioTherapeutics	-3.13%	-1.90%	+6.16%	0.00%	+72.22%
PRTO Proteon Therapeutics	+3.19%	+6.60%	-3.58%	+3.19%	+62.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVM CEL-SCI	0.5231 of 5 stars	0.0	4.0	0.0	0.0	0.0	1.7	0.6
IKT Inhibikase Therapeutics	2.0703 of 5 stars	3.3	2.0	0.0	0.0	3.7	0.0	0.6
PLX Protalix BioTherapeutics	3.0231 of 5 stars	3.5	2.0	0.0	0.0	2.1	1.7	1.9
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVM CEL-SCI	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	261.11% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	867.74% Upside
PRTO Proteon Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVM CEL-SCI	N/A	N/A	N/A	N/A	$0.15 per share	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PLX Protalix BioTherapeutics	$61.95M	1.99	$0.09 per share	17.80	$0.47 per share	3.30
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	($0.06) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVM CEL-SCI	-$26.92M	-$9.77	N/A	N/A	N/A	N/A	-238.05%	-104.65%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.07	N/A	5.00	N/A	-21.03%	-30.89%	-11.74%	N/A
PRTO Proteon Therapeutics	-$20.73M	-$1.15	N/A	N/A	N/A	N/A	N/A	-118.68%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVM CEL-SCI	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
PRTO Proteon Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVM CEL-SCI	0.66	1.07	1.09
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PLX Protalix BioTherapeutics	N/A	1.98	1.27
PRTO Proteon Therapeutics	N/A	5.98	5.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVM CEL-SCI	12.08%
IKT Inhibikase Therapeutics	3.81%
PLX Protalix BioTherapeutics	16.53%
PRTO Proteon Therapeutics	23.03%

Insider Ownership

Company	Insider Ownership
CVM CEL-SCI	9.93%
IKT Inhibikase Therapeutics	7.30%
PLX Protalix BioTherapeutics	6.50%
PRTO Proteon Therapeutics	45.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVM CEL-SCI	43	6.88 million	64.67 million	Optionable
IKT Inhibikase Therapeutics	6	74.52 million	66.18 million	Not Optionable
PLX Protalix BioTherapeutics	200	79.73 million	69.00 million	Optionable
PRTO Proteon Therapeutics	17	22.18 million	N/A	Not Optionable

PRTO, IKT, PLX, and CVM Headlines

Recent News About These Companies

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan

November 9, 2024 | markets.businessinsider.com

Protara Therapeutics (TARA) Earnings Dates & Reports

November 1, 2024 | investing.com

ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James

October 29, 2024 | markets.businessinsider.com

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday

October 28, 2024 | msn.com

ProQR Announces Major Share Offering Agreement

October 25, 2024 | markets.businessinsider.com

Seaport raises $225m to advance portfolio of neuropsychiatric prodrugs

October 22, 2024 | msn.com

Understanding Neurodegenerative Disease with Prion Research

September 13, 2024 | the-scientist.comT

Prodrugs and patents: Enhancing therapy adherence and reducing side effects

September 11, 2024 | msn.com

iPhone 13 Pro vs. iPhone 16 Pro: 65+ Upgrades to Expect

September 8, 2024 | macrumors.comM

PS5 Pro: the latest on rumored specs, price, and release date speculation

August 30, 2024 | techradar.comT

Rapport Therapeutics Seeks IPO For CNS Treatment Programs

May 22, 2024 | seekingalpha.com

PTC Therapeutics: Q1 Earnings Snapshot

April 25, 2024 | timesunion.comT

Protara Therapeutics Inc (TARA)

April 24, 2024 | investing.com

iPad Pro

February 2, 2024 | macrumors.comM

Esperion Therapeutics Inc ESPR

November 5, 2023 | morningstar.comM

The Latest Analyst Ratings for Revance Therapeutics

September 20, 2023 | benzinga.com

ENLV - Enlivex Therapeutics Ltd.

June 6, 2023 | finance.yahoo.com

Prelude Therapeutics Insider Trades Send a Signal

May 25, 2023 | benzinga.com

Global Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growth

May 22, 2023 | benzinga.com

The best iPhone 14 Pro deals for May 2023

May 18, 2023 | techradar.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTO, IKT, PLX, and CVM Company Descriptions

CEL-SCI NYSE:CVM

$10.43 +1.12 (+12.03%)

Closing price 04:00 PM Eastern

Extended Trading

$10.46 +0.03 (+0.24%)

As of 05:51 PM Eastern

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Inhibikase Therapeutics NYSE:IKT

$1.80 -0.04 (-2.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 0.00 (0.00%)

As of 04:20 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Protalix BioTherapeutics NYSE:PLX

$1.55 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.56 +0.00 (+0.32%)

As of 04:20 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Proteon Therapeutics NASDAQ:PRTO

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time